Clinical Trial

European Disease Registry on Retinopathy of Prematurity (ROP)

Study acronym: EU-ROP
Recruiting
View on ClinicalTrials.gov →
Summary
The EU-ROP registry is a European wide multicenter non-interventional observational registry study intended to run open-ended in as many countries as possible including infants treated for retinopathy of prematurity irrespective of the used treatment modality. The registry is strictly observational; only clinical routine data is collected, no study-specific examinations or interventions are to be performed. The aim of the EU-ROP registry is to collect information on as many patients as possible treated for ROP in Europe. Both the number of study centers as well as the number of patients to be included into the registry are not limited. The primary objective is to describe the typical clinical features of infants with severe ROP, variations in phenotype, and the clinical progression of the disease over time (natural history) in different European countries as well as to study treatment patterns, follow-up patterns, as well as long-term outcomes.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-06-16; most recent amendment 2024-01-22.
Status change: Not Yet Recruiting → Recruiting 2021-08-17
Trial Details
NCT Number NCT04939571
Lead Sponsor University Medicine Greifswald
Conditions Retinopathy of Prematurity
Enrollment 3,000 participants
Start Date 2021-08-06
Primary Completion 2038-08 (estimated)
Study Completion 2039-08 (estimated)
Updated on ClinicalTrials.gov 2024-01-24